Enveric Biosciences Narrows Quarterly Loss to $2.5 Million as Experimental Neurological Drug Advances Toward Human Trials

0
13
Dr. Joseph Tucker

CAMBRIDGE, Mass.–Enveric Biosciences reported a smaller third-quarter loss as the biotechnology company continued preparing its lead experimental drug, EB-003, for its first human clinical trial, supported by new preclinical findings related to brain activity, drug metabolism and its potential non-hallucinogenic properties.

The company recorded a net loss attributable to stockholders of $2.5 million for the quarter ended September 30, 2026, compared with $3.4 million during the same period last year.

Loss per share narrowed to $0.57 from $10.81 a year earlier. The prior-year results included a $1.5 million deemed dividend associated with a warrant inducement that did not recur in 2026.

Enveric ended the quarter with approximately $5.6 million in cash.

The company is developing treatments for psychiatric and neurological disorders using compounds designed to promote neuroplasticity, the brain’s ability to form and reorganize neural connections.

Its lead candidate, EB-003, is being developed to produce therapeutic effects associated with neuroplasticity without the hallucinogenic experiences typically linked to traditional psychedelic compounds.

Enveric is completing the studies required to support an Investigational New Drug application with the U.S. Food and Drug Administration, which would allow the company to begin evaluating EB-003 in humans.

“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. “The data generated during the quarter and in recent weeks strengthen the foundation for this next stage and reinforce the opportunity to develop EB-003 as a differentiated treatment for psychiatric and neurological disorders.”

During the quarter, Enveric completed laboratory studies examining the absorption, distribution, metabolism, excretion and toxicity characteristics of EB-003.

The findings suggested favorable absorption and metabolic properties, along with a potentially reduced likelihood of interactions with other medications.

Additional laboratory testing using GloSensor and BRET assay technologies provided evidence supporting the company’s prediction that EB-003 could produce neuroplasticity-related effects without causing hallucinations.

The company also reported results from a preclinical quantitative electroencephalography (qEEG) study that examined how EB-003 affects electrical activity in the brain.

The findings demonstrated evidence that the compound reaches the central nervous system and produces a pattern of brain activity distinct from dimethyltryptamine (DMT), a psychedelic substance known for its hallucinogenic effects.

Enveric said the results could support the use of qEEG measurements as a biomarker in future human trials, potentially helping researchers evaluate drug activity and determine appropriate dosing.

“Recently completed studies of EB-003 have provided important, complementary evidence demonstrating its differentiated profile and potential advantages. Independent assay platforms, including GloSensor™ and BRET, have consistently supported its predicted non-hallucinogenic profile, while our completed in vitro ADMET studies indicate favorable absorption and metabolic properties and a reduced potential for drug-drug interactions. The qEEG study adds functional evidence of brain penetration and a pattern of brain activity distinct from dimethyltryptamine (DMT). It also supports evaluating qEEG in human studies to connect drug exposure with brain activity and help guide dose selection.”

Enveric is seeking to develop a treatment that could offer some of the potential therapeutic benefits being investigated in psychedelic-based medicine without requiring patients to experience hallucinations.

The company believes such an approach could eventually simplify treatment administration and potentially make therapies more accessible in outpatient settings.

However, EB-003 remains in preclinical development, and its safety and effectiveness in humans have not yet been established.

“As the FDA continues to define the regulatory framework for psychedelic-inspired therapies, we believe EB-003’s design has the potential to offer advantages in clinical development while supporting broader patient access and potential commercial adoption,” Tucker said. “By seeking to harness the therapeutic potential of neuroplasticity without requiring a hallucinogenic experience, our approach could support a simpler outpatient treatment model. The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”

Beyond EB-003, Enveric received a U.S. patent allowance covering next-generation, non-hallucinogenic mescaline derivatives within its EVM401 series of compounds.

The patent development expands the company’s intellectual property portfolio as it investigates additional potential treatments for neurological and psychiatric conditions.

Enveric also highlighted the FDA’s finalized guidance concerning clinical investigations of psychedelic and psychedelic-inspired therapeutics, which the company said could help establish clearer regulatory expectations for developers in the emerging field.

The company is continuing its final preclinical and regulatory preparations for EB-003 as it works toward submitting its Investigational New Drug application and initiating a Phase 1 clinical trial.

Leave A Reply

Please enter your comment!
Please enter your name here